Streetbeat News

Analyst Ratings

SEDG

Goldman Sachs analyst Brian Lee has maintained a Neutral rating on SolarEdge Technologies (NASDAQ:SEDG) and lowered the price target from $131 to $77.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 3:00 pm

KRTX

Karuna Therapeutics (NASDAQ:KRTX) has received mostly bullish ratings from analysts in the last quarter. In the last 3 months, 6 analysts have offered 12-month price targets for Karuna Therapeutics, with an average price target of $257.83, a 12.7% decrease from the previous average price target of $295.33.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 3:00 pm

IDXX

In the last quarter, IDEXX Laboratories (NASDAQ:IDXX) received various analyst ratings, with 1 bullish, 2 somewhat bullish, and 2 indifferent. The average 12-month price target for the company is $520.4, representing a 6.84% decrease from the previous average price target of $558.60.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 3:00 pm

UNM

Over the past 3 months, 5 analysts have published their opinion on Unum Gr (NYSE:UNM) stock. The company has an average price target of $57.6 with a high of $63.00 and a low of $54.00. The average price target has increased by 1.41% over the past month.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 3:00 pm

MIRM

Mirum Pharmaceuticals (NASDAQ:MIRM) has received 9 bullish ratings from analysts in the last quarter, with an average 12-month price target of $67.33, a decrease of 10.62% from the previous average price target of $75.33. No bearish or indifferent ratings were observed.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 3:00 pm

ETR

Over the past 3 months, 12 analysts have published their opinion on Entergy (NYSE:ETR) stock. The average price target is $104.33, implying an upside from the current price of $98.66. This represents a 4.63% decrease from the previous average price target of $109.40.

Portfolio Pulse from Benzinga Insights

November 03, 2023 | 3:00 pm

MCRB

Goldman Sachs analyst Chris Shibutani has maintained a 'Sell' rating on Seres Therapeutics (NASDAQ:MCRB) and lowered the price target from $4 to $1.25.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:58 pm

SNDR

Goldman Sachs analyst Jordan Alliger has maintained a Neutral rating on Schneider National (NYSE:SNDR) and lowered the price target from $32 to $28.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:57 pm

RDFN

Wedbush analyst Jay McCanless has maintained a Neutral rating on Redfin (NASDAQ:RDFN) and lowered the price target from $11 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:57 pm

PHAT

Goldman Sachs analyst Paul Choi maintains a Neutral rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and raises the price target from $9 to $10.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 2:55 pm